Capecitabine Maintenance Therapy Following Capecitabine Combined With Docetaxel in Treatment of mBC
Capecitabine Maintenance Therapy Following Capecitabine Combined With Docetaxel in Treatment of mBC
Bio2RDF identifier
NCT01917279
Bio2RDF namespace
clinicaltrials
Bio2RDF uri
http://bio2rdf.org/clinicaltrials:NCT01917279
identifiers.org URI
acronym [clinicaltrials_vocabulary:acronym]
anticipated enrollment [clinicaltrials_vocabulary:anticipated-enrollment]
arm group [clinicaltrials_vocabulary:arm-group]
authority [clinicaltrials_vocabulary:authority]
brief summary [clinicaltrials_vocabulary:brief-summary]
It is a phase III trial ...... tic breast
cancer(mBC).
brief title [clinicaltrials_vocabulary:brief-title]
Capecitabine Maintenance Thera ...... Docetaxel in Treatment of mBC
clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]
collaborator [clinicaltrials_vocabulary:collaborator]
completion date [clinicaltrials_vocabulary:completion-date]
2018-09-01T00:00:00Z
condition [clinicaltrials_vocabulary:condition]
condition browse [clinicaltrials_vocabulary:condition-browse]
condition mesh [clinicaltrials_vocabulary:condition-mesh]
country [clinicaltrials_vocabulary:country]
download date [clinicaltrials_vocabulary:download-date]
ClinicalTrials.gov processed this data on August 10, 2015
eligibility [clinicaltrials_vocabulary:eligibility]
firstreceived date [clinicaltrials_vocabulary:firstreceived-date]
2013-07-19T00:00:00Z
has expanded access [clinicaltrials_vocabulary:has-expanded-access]
intervention [clinicaltrials_vocabulary:intervention]
intervention browse [clinicaltrials_vocabulary:intervention-browse]
is fda regulated [clinicaltrials_vocabulary:is-fda-regulated]
keyword [clinicaltrials_vocabulary:keyword]
Antimetabolites
Antineoplastic Agents
Capecitabine
Maintenance chemotherapy
Metastatic Breast Cancer
Metronomic chemotherapy
Therapeutic Uses
Tubulin Modulators
lastchanged date [clinicaltrials_vocabulary:lastchanged-date]
2013-11-21T00:00:00Z
lead sponsor [clinicaltrials_vocabulary:lead-sponsor]
location [clinicaltrials_vocabulary:location]
nct id [clinicaltrials_vocabulary:nct-id]
NCT01917279
number of arms [clinicaltrials_vocabulary:number-of-arms]
official title [clinicaltrials_vocabulary:official-title]
A Randomized Phase III Study o ...... ative Metastatic Breast Cancer
org study id [clinicaltrials_vocabulary:org-study-id]
overall contact [clinicaltrials_vocabulary:overall-contact]
overall contact backup [clinicaltrials_vocabulary:overall-contact-backup]
overall official [clinicaltrials_vocabulary:overall-official]
overall status [clinicaltrials_vocabulary:overall-status]
oversight [clinicaltrials_vocabulary:oversight]
phase [clinicaltrials_vocabulary:phase]
primary completion date [clinicaltrials_vocabulary:primary-completion-date]
2016-07-01T00:00:00Z
responsible party [clinicaltrials_vocabulary:responsible-party]
source [clinicaltrials_vocabulary:source]
start date [clinicaltrials_vocabulary:start-date]
2013-10-01T00:00:00Z
study design [clinicaltrials_vocabulary:study-design]
study type [clinicaltrials_vocabulary:study-type]
url [clinicaltrials_vocabulary:url]
verification date [clinicaltrials_vocabulary:verification-date]
2013-11-01T00:00:00Z
identifier
clinicaltrials:NCT01917279
title
Capecitabine Maintenance Thera ...... Docetaxel in Treatment of mBC
@en